Why the study?
A significant gap remains in understanding the pathogenesis of hangover syndrome, hampering the development of metabolic treatments, while the efficacy of most existing therapies lacks support from clinical trials.
Answers are grounded in this paper and cite their sources.
Current treatments for Hangover Syndrome lack support from clinical trials, highlighting a gap in understanding its pathogenesis and metabolic correction.
It was shown, that there is a significant gap in the understanding of pathogenesis of HS, which hamper the elaboration of means of metabolic correction of this condition. The target of majority of currently existing means of treatment of HS is one of the pathogenic mechanisms of HS. The effectiveness of majority of currently existing medicine is not supported by the results of clinical trials.
No takes yet. Share an insight, caveat, or question.
YE Razvodovsky (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: